Literature DB >> 21996700

Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response.

Jacqueline M Achkar1, Elizabeth R Jenny-Avital.   

Abstract

Latent Mycobacterium tuberculosis infection (LTBI) and active tuberculosis (TB) are 2 ends of a spectrum of states ranging from asymptomatic infection to overt disease. While progressing from LTBI to TB, patients often undergo asymptomatic states with detectable manifestations indicative of disease. Such asymptomatic disease states frequently remain undiagnosed, and their manifestations and duration are mostly dependent on host immune response. Various terms referring to such states are used in the literature, often interchangeably and without explicit definitions. Defining these intermediate states in concrete terms is important for pragmatic reasons, as they might impact upon the diagnostic performance of TB biomarkers and could also present targets for therapeutic interventions. We here propose definitions for 2 commonly used terms, "incipient" and "subclinical" TB, to describe asymptomatic disease states occurring at opposite ends of the host response spectrum. We propose using the term "incipient TB" when referring to early, contained disease in asymptomatic, relatively immunocompetent persons. In contrast, we propose using the term "subclinical TB" to refer to disease in asymptomatic, immunocompromised individuals in whom it is largely associated with loss of effective containment. The rationale for this article is to facilitate the discussion of such early disease states, especially in relation to their impact on TB biomarker discovery and assessment of new diagnostics, and with regard to treatment decisions and ultimately outcome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21996700      PMCID: PMC3192549          DOI: 10.1093/infdis/jir451

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  82 in total

1.  Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

Authors:  F Tubach; D Salmon; P Ravaud; Y Allanore; P Goupille; M Bréban; B Pallot-Prades; S Pouplin; A Sacchi; R M Chichemanian; S Bretagne; D Emilie; M Lemann; O Lortholary; O Lorthololary; X Mariette
Journal:  Arthritis Rheum       Date:  2009-07

Review 2.  Advances in immunotherapy for tuberculosis treatment.

Authors:  Gavin J Churchyard; Gilla Kaplan; Dorothy Fallows; Robert S Wallis; Philip Onyebujoh; Graham A Rook
Journal:  Clin Chest Med       Date:  2009-12       Impact factor: 2.878

Review 3.  Biomarkers for tuberculosis disease status and diagnosis.

Authors:  Mark Doherty; Robert S Wallis; Alimuddin Zumla
Journal:  Curr Opin Pulm Med       Date:  2009-05       Impact factor: 3.155

4.  The likelihood of an indeterminate test result from a whole-blood interferon-gamma release assay for the diagnosis of Mycobacterium tuberculosis infection in children correlates with age and immune status.

Authors:  Thomas Haustein; Deborah A Ridout; John C Hartley; Urvashi Thaker; Delane Shingadia; Nigel J Klein; Vas Novelli; Garth L J Dixon
Journal:  Pediatr Infect Dis J       Date:  2009-08       Impact factor: 2.129

5.  Adalimumab treatment of life-threatening tuberculosis.

Authors:  Robert S Wallis; Cloete van Vuuren; Samantha Potgieter
Journal:  Clin Infect Dis       Date:  2009-05-15       Impact factor: 9.079

6.  Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients.

Authors:  R Mutetwa; C Boehme; M Dimairo; T Bandason; S S Munyati; D Mangwanya; S Mungofa; A E Butterworth; P R Mason; E L Corbett
Journal:  Int J Tuberc Lung Dis       Date:  2009-10       Impact factor: 2.373

7.  Blinded evaluation of commercial urinary lipoarabinomannan for active tuberculosis: a pilot study.

Authors:  P Daley; J S Michael; P Hmar; A Latha; P Chordia; D Mathai; K R John; M Pai
Journal:  Int J Tuberc Lung Dis       Date:  2009-08       Impact factor: 2.373

8.  Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis.

Authors:  Klaus Reither; Elmar Saathoff; Jutta Jung; Lilian T Minja; Inge Kroidl; Eiman Saad; Jim F Huggett; Elias N Ntinginya; Lucas Maganga; Leonard Maboko; Michael Hoelscher
Journal:  BMC Infect Dis       Date:  2009-08-28       Impact factor: 3.090

Review 9.  The spectrum of latent tuberculosis: rethinking the biology and intervention strategies.

Authors:  Clifton E Barry; Helena I Boshoff; Véronique Dartois; Thomas Dick; Sabine Ehrt; JoAnne Flynn; Dirk Schnappinger; Robert J Wilkinson; Douglas Young
Journal:  Nat Rev Microbiol       Date:  2009-10-26       Impact factor: 60.633

10.  Eliminating latent tuberculosis.

Authors:  Douglas B Young; Hannah P Gideon; Robert J Wilkinson
Journal:  Trends Microbiol       Date:  2009-04-16       Impact factor: 17.079

View more
  44 in total

1.  Comparative evaluation of profiles of antibodies to mycobacterial capsular polysaccharides in tuberculosis patients and controls stratified by HIV status.

Authors:  Xian Yu; Rafael Prados-Rosales; Elisabeth R Jenny-Avital; Katherine Sosa; Arturo Casadevall; Jacqueline M Achkar
Journal:  Clin Vaccine Immunol       Date:  2011-12-14

Review 2.  Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis.

Authors:  Jacqueline M Achkar; Rafael Prados-Rosales
Journal:  Curr Opin Immunol       Date:  2018-04-12       Impact factor: 7.486

3.  Antibodies against Mycobacterial proteins as biomarkers for HIV-associated smear-negative tuberculosis.

Authors:  Michael Siev; Douglas Wilson; Supreet Kainth; Victoria O Kasprowicz; Catherine M Feintuch; Elizabeth R Jenny-Avital; Jacqueline M Achkar
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

Review 4.  Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection.

Authors:  Paul K Drain; Kristina L Bajema; David Dowdy; Keertan Dheda; Kogieleum Naidoo; Samuel G Schumacher; Shuyi Ma; Erin Meermeier; David M Lewinsohn; David R Sherman
Journal:  Clin Microbiol Rev       Date:  2018-07-18       Impact factor: 26.132

Review 5.  B cells and antibodies in the defense against Mycobacterium tuberculosis infection.

Authors:  Jacqueline M Achkar; John Chan; Arturo Casadevall
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

6.  Identification of Antibody Targets for Tuberculosis Serology using High-Density Nucleic Acid Programmable Protein Arrays.

Authors:  Lusheng Song; Garrick Wallstrom; Xiaobo Yu; Marika Hopper; Jennifer Van Duine; Jason Steel; Jin Park; Peter Wiktor; Peter Kahn; Al Brunner; Douglas Wilson; Elizabeth R Jenny-Avital; Ji Qiu; Joshua Labaer; D Mitchell Magee; Jacqueline M Achkar
Journal:  Mol Cell Proteomics       Date:  2017-02-21       Impact factor: 5.911

Review 7.  Antibody-mediated immunity against tuberculosis: implications for vaccine development.

Authors:  Jacqueline M Achkar; Arturo Casadevall
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023

8.  Spontaneous latency in a rabbit model of pulmonary tuberculosis.

Authors:  Selvakumar Subbian; Liana Tsenova; Paul O'Brien; Guibin Yang; Nicole L Kushner; Sven Parsons; Blas Peixoto; Dorothy Fallows; Gilla Kaplan
Journal:  Am J Pathol       Date:  2012-09-05       Impact factor: 4.307

9.  Mycobacterium tuberculosis infection is exacerbated in mice lacking lecithin:retinol acyltransferase.

Authors:  Steven E Trasino; Xiao-Han Tang; Carolina Trujillo; Jaclynn Andres; Sabine Ehrt; Lorraine J Gudas
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-08-05       Impact factor: 5.187

10.  Utilization and Clinical Value of Diagnostic Modalities for Tuberculosis in a High HIV Prevalence Setting.

Authors:  Stephanie Gati; Rhoda Chetty; Douglas Wilson; Jacqueline M Achkar
Journal:  Am J Trop Med Hyg       Date:  2018-06-07       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.